Short Interest in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM) Decreases By 2.0%

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 1,189,611 shares, a decline of 2.0% from the October 15th total of 1,214,174 shares. Currently, 3.3% of the shares of the stock are short sold. Based on an average daily volume of 21,451 shares, the days-to-cover ratio is currently 55.5 days.

Shares of ZOM stock opened at $1.78 on Friday. Zomedica Pharmaceuticals Corp has a twelve month low of $1.36 and a twelve month high of $2.98.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last posted its quarterly earnings data on Thursday, August 9th. The company reported ($0.04) EPS for the quarter. As a group, equities analysts forecast that Zomedica Pharmaceuticals Corp will post -0.11 EPS for the current fiscal year.

In related news, Director James Lebar sold 200,000 shares of the business’s stock in a transaction dated Tuesday, August 28th. The shares were sold at an average price of $2.15, for a total value of $430,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 57.28% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Northern Trust Corp acquired a new position in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the 2nd quarter valued at about $144,000. Bank of New York Mellon Corp acquired a new position in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the 2nd quarter valued at about $160,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the 2nd quarter valued at about $167,000. BlackRock Inc. increased its stake in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 9.4% during the 3rd quarter. BlackRock Inc. now owns 1,727,098 shares of the company’s stock valued at $3,230,000 after acquiring an additional 147,828 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its stake in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 6,107.1% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 12,079,080 shares of the company’s stock valued at $27,178,000 after acquiring an additional 11,884,480 shares during the last quarter. 15.79% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/11/10/short-interest-in-zomedica-pharmaceuticals-corp-nyseamerican-zom-decreases-by-2-0.html.

About Zomedica Pharmaceuticals Corp (NYSEAMERICAN)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

Featured Article: Day Trading

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply